<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137912">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968681</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2013-066</org_study_id>
    <nct_id>NCT01968681</nct_id>
  </id_info>
  <brief_title>Treatment of Nevus Flammeus With Alexandrite Laser</brief_title>
  <official_title>Treatment of Nevus Flammeus With Alexandrite Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Private practice Boom Belgien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nevus flammeus is a congenital vascular malformation. Nevus flammeus is traditionally
      treated with pulsed dye lasers (PDL); however, around 20 percent of patients are poor
      responders and do not get satisfactory results from pulsed dye laser treatments.

      Small studies with alexandrite lasers indicate that this may be an alternative treatment for
      individuals with nevus flammeus. This study assesses the clinical effect and side effects of
      alexandrite laser treatment for nevus flammeus using different treatment settings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in clinical appearance on a 10-point scale</measure>
    <time_frame>6-8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin reflectance measurement to assess degree of redness</measure>
    <time_frame>6-8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin reflectance to assess degree of pigmentation</measure>
    <time_frame>6-8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical assessment of pigmentation</measure>
    <time_frame>6-8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Clinical assessment of scar tissue formation</measure>
    <time_frame>6-8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nevus Flammeus</condition>
  <arm_group>
    <arm_group_label>Alexandrite laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Alexandrite laser</intervention_name>
    <description>3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.</description>
    <arm_group_label>Alexandrite laser treatment</arm_group_label>
    <other_name>Candela Gentle Max</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10 or more years of age

          -  Fitzpatrick Skin Type I-III

          -  Previously untreated or pulsed dye laser-insufficiently treated nevus flammeus

          -  Nevus flammeus size minimum 8 x 2 centimeter within one anatomical region

          -  Written and oral informed consent

        Exclusion Criteria:

          -  Known light sensibility toward visible light

          -  Tendency to develop hypertrophic scars or keloids

          -  Fitzpatrick Skin Type IV-VI

          -  Individuals, that are obviously pigmented due to recent sun exposure or sun beds

          -  Treatment with systemic retinoids within 6 months

          -  Pregnancy and lactation

          -  Unwillingness to complete protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merete Haedersdal, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merete Haedersdal, Professor</last_name>
    <email>merete.haedersdal@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Private Dermatology Practice</name>
      <address>
        <city>Boom</city>
        <zip>2850</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merete Haedersdal, Professor</last_name>
      <email>merete.haedersdal@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Berit Carlsen, MD</last_name>
      <email>berit.christina.carlsen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Berit Carlsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 21, 2013</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Merete Haedersdal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nevus</mesh_term>
    <mesh_term>Nevus, Pigmented</mesh_term>
    <mesh_term>Port-Wine Stain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
